Sonic Incytes
7
0
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.3%
1 terminated/withdrawn out of 7 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
100%
2 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
Role: collaborator
Ultrasound Liver Imaging for Classification of Metabolic Dysfunction-associated Steatotic Liver Disease
Role: collaborator
Velacur by Sonic Incytes for Portal Hypertension
Role: collaborator
Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease
Role: collaborator
Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease
Role: collaborator
The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF
Role: lead
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
Role: lead
All 7 trials loaded